Herbas VPB

Print
EN | LT
Supplementary protection
LT - Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
EN - METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES
SPC
(11) Number of the document C 2068874
(68) Number of the document 2068874
(21) Application number for Supplementary Protection Certificate PA 2016 031
(22) Date of filing the application 2016-10-27
(41) Date of publication of the application 2016-11-10
Date of publication of SPC 2018-11-12
(24) Date of coming into effect of SPC 2027-08-08
Applicant
(71) AbbVie Biotherapeutics Inc., 1500 Seaport Boulevard, Redwood City, CA 94063, US
Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215-5450, US
Grantee
(73) AbbVie Biotherapeutics Inc., 1500 Seaport Boulevard, Redwood City, CA 94063, US
Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215-5450, US
Attorney or representative
(74) Aušra PAKĖNIENĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
(93) EU/1/16/1088, 2016-05-11
Calculated date of expiry of the SPC
(94) 2031-05-13
Name of the product protected by the basic patent
(95) Elotuzumabas
Legal status
SPC granted
Last update date 2021-11-25